Literature DB >> 26590581

Current surgical strategies for malignant pleural mesothelioma.

Teruhisa Takuwa1, Seiki Hasegawa2.   

Abstract

Malignant pleural mesothelioma (MPM) is associated with a poor prognosis. The main components of multimodality treatment include surgery, chemotherapy, and radiation therapy. Surgery remains controversial. Two procedures are currently offered: extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D). The recent scientific literature suggests that P/D is a well-tolerated procedure, with the potential of becoming a default procedure in multimodality regimens. However, the precise treatment schemes and surgical procedures are yet to be established. In our study, we review the advantages and disadvantages of EPP and P/D, summarize the post-EPP and post-P/D observations (including mortality, morbidity, and median survival time), and discuss the choice of surgical technique (EPP vs. P/D). Moreover, we highlight the aspects of the multimodality treatments that are offered to MPM patients, including chemotherapy, radiotherapy, intensity-modulated radiation therapy, and other types of therapy.

Entities:  

Keywords:  Extrapleural pneumonectomy; Malignant pleural mesothelioma; Pleurectomy/decortication; Surgical therapy

Mesh:

Year:  2015        PMID: 26590581     DOI: 10.1007/s00595-015-1275-3

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  57 in total

1.  Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure.

Authors:  Ottavio Rena; Caterina Casadio
Journal:  Lung Cancer       Date:  2012-01-11       Impact factor: 5.705

2.  The MARS feasibility trial: conclusions not supported by data.

Authors:  Walter Weder; Rolf A Stahel; Paul Baas; Urania Dafni; Marc de Perrot; Brian C McCaughan; Takashi Nakano; Harvey I Pass; Bruce W S Robinson; Valerie W Rusch; David J Sugarbaker; Nico van Zandwijk
Journal:  Lancet Oncol       Date:  2011-11       Impact factor: 41.316

3.  Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection.

Authors:  David J Sugarbaker; Ritu R Gill; Beow Y Yeap; Andrea S Wolf; Marcelo C DaSilva; Elizabeth H Baldini; Raphael Bueno; William G Richards
Journal:  J Thorac Cardiovasc Surg       Date:  2013-02-21       Impact factor: 5.209

4.  Multimodal management of malignant pleural mesothelioma: where are we today?

Authors:  Paul E Van Schil; Isabelle Opitz; Walter Weder; Christophe De Laet; Andreas Domen; Patrick Lauwers; Jeroen M Hendriks; Jan P Van Meerbeeck
Journal:  Eur Respir J       Date:  2014-02-13       Impact factor: 16.671

5.  Interim results of pleurectomy/decortication and intraoperative intrapleural hyperthermic cisplatin perfusion for patients with malignant pleural mesothelioma intolerable to extrapleural pneumonectomy.

Authors:  Hironori Ishibashi; Masashi Kobayashi; Chihiro Takasaki; Kenichi Okubo
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-03-07

6.  Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.

Authors:  Federico Rea; Giuseppe Marulli; Luigi Bortolotti; Cristiano Breda; Adolfo Gino Favaretto; Lucio Loreggian; Francesco Sartori
Journal:  Lung Cancer       Date:  2007-04-02       Impact factor: 5.705

7.  The management of malignant pleural mesothelioma; single centre experience in 10 years.

Authors:  Tarek Aziz; Ali Jilaihawi; Dhruva Prakash
Journal:  Eur J Cardiothorac Surg       Date:  2002-08       Impact factor: 4.191

8.  Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors.

Authors:  Tristan D Yan; Michael Boyer; Mo Mo Tin; Daniel Wong; Catherine Kennedy; Jocelyn McLean; Paul G Bannon; Brian C McCaughan
Journal:  J Thorac Cardiovasc Surg       Date:  2009-03-09       Impact factor: 5.209

9.  Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies.

Authors:  David J Sugarbaker; Michael T Jaklitsch; Raphael Bueno; William Richards; Jeanne Lukanich; Steven J Mentzer; Yolonda Colson; Phillip Linden; Michael Chang; Leah Capalbo; Elizabeth Oldread; Siyamek Neragi-Miandoab; Scott J Swanson; Lambros S Zellos
Journal:  J Thorac Cardiovasc Surg       Date:  2004-07       Impact factor: 5.209

10.  Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.

Authors:  Raja M Flores; Harvey I Pass; Venkatraman E Seshan; Joseph Dycoco; Maureen Zakowski; Michele Carbone; Manjit S Bains; Valerie W Rusch
Journal:  J Thorac Cardiovasc Surg       Date:  2008-02-14       Impact factor: 5.209

View more
  10 in total

1.  Perspective on malignant pleural mesothelioma diagnosis and treatment.

Authors:  Ori Wald; David J Sugarbaker
Journal:  Ann Transl Med       Date:  2016-03

2.  Is Pleurectomy/Decortication Superior to Extrapleural Pneumonectomy for Patients with Malignant Pleural Mesothelioma? A Single-Institutional Experience.

Authors:  Takuro Miyazaki; Naoya Yamasaki; Tomoshi Tsuchiya; Keitaro Matsumoto; Ryotaro Kamohara; Go Hatachi; Takeshi Nagayasu
Journal:  Ann Thorac Cardiovasc Surg       Date:  2018-01-23       Impact factor: 1.520

3.  SMO mutations confer poor prognosis in malignant pleural mesothelioma.

Authors:  Diego Signorelli; Claudia Proto; Laura Botta; Annalisa Trama; Marcello Tiseo; Giulia Pasello; Giuseppe Lo Russo; Alessandra Fabbri; Martina Imbimbo; Adele Busico; Arsela Prelaj; Roberto Ferrara; Giulia Galli; Alessandro De Toma; Elena Tamborini; Ugo Pastorino; Filippo de Braud; Gemma Gatta; Marina Chiara Garassino; Monica Ganzinelli
Journal:  Transl Lung Cancer Res       Date:  2020-10

4.  CUL4B is a Potential Novel Prognostic Biomarker and is Correlated with Immune Infiltrates in Malignant Pleural Mesothelioma.

Authors:  Lu Liu; Ruting Hui; Tianyang Zeng; Xuetao Yang; Qingchen Wu; Tao Yang
Journal:  Int J Gen Med       Date:  2022-05-03

5.  FAS and FASL genetic polymorphisms impact on clinical outcome of malignant pleural mesothelioma.

Authors:  Manal El-Hamamsy; Ramy R Ghali; Amr S Saad; Sara M Shaheen; Ahmed M Salem
Journal:  Onco Targets Ther       Date:  2016-11-07       Impact factor: 4.147

6.  Outcomes of the Multimodal Treatment of Malignant Pleural Mesiothelioma: The Role of Surgery.

Authors:  Bub-Se Na; Ji Seong Kim; Kwanyong Hyun; In Kyu Park; Chang Hyun Kang; Young Tae Kim
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2018-02-05

Review 7.  Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma.

Authors:  Yoshitaka Sekido
Journal:  Cancers (Basel)       Date:  2018-03-22       Impact factor: 6.639

8.  Establishment and Characterization of Patient-Derived Xenografts (PDXs) of Different Histology from Malignant Pleural Mesothelioma Patients.

Authors:  Roberta Affatato; Paolo Mendogni; Alessandro Del Gobbo; Stefano Ferrero; Francesca Ricci; Massimo Broggini; Lorenzo Rosso
Journal:  Cancers (Basel)       Date:  2020-12-20       Impact factor: 6.639

9.  Low-dose photon irradiation induces invasiveness through the SDF-1α/CXCR4 pathway in malignant mesothelioma cells.

Authors:  Yoshikane Yamauchi; Seyer Safi; Lena Orschiedt; Adriane Gardyan; Stephan Brons; Juliane Rieber; Nils H Nicolay; Peter E Huber; Martin Eichhorn; Hendrik Dienemann; Felix J F Herth; Klaus-Josef Weber; Jürgen Debus; Hans Hoffmann; Stefan Rieken
Journal:  Oncotarget       Date:  2017-07-10

10.  Tumor Growth Assessment by Computed Tomography Perfusion Imaging (CTPI), Perfusion-Weighted Imaging (PWI), and Diffusion-Weighted Imaging (DWI) in a Rabbit Pleural Squamous Cell Carcinoma VX2-Implanted Model.

Authors:  Qiang Zhang; Caixia Ba; Mingmin Zhang; Zhaoxin Liu; Baoqi Shi; Fuliang Qi; Haijiang Wang; Yuan Lv; Haijiao Jin; Xiaochuan Yang
Journal:  Med Sci Monit       Date:  2018-09-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.